Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02607553 · ClinicalTrials.gov registry record · Phase 2
Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA
A Phase 2 study, sponsored by GenSpera.
- Completed
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT02607553: Completed Phase 2 study, sponsored by GenSpera.
NCT02607553 is a Phase 2 study that has completed, run by GenSpera. The registered enrollment target is 2 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02607553, a Phase 2 study, has completed, sponsored by GenSpera.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
An open-label, single-arm, single-center Phase II study to evaluate the safety and activity of G-202 in patients with clear cell renal cell carcinoma that expresses PSMA
Primary Outcome
Use RECIST criteria to assess the clinical activity of G-202 administered by intravenous infusion daily for 3 consecutive days of a 28-day cycle
Interventions
- DRUG G-202
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2016-06 |
| Est. Completion | 2017-02 |
| Phase | Phase 2 |
What the finished NCT02607553 record still lists
NCT02607553 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which G-202 is the first listed.
NCT02607553 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02607553 about?
NCT02607553 is a clinical study titled "Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA". An open-label, single-arm, single-center Phase II study to evaluate the safety and activity of G-202 in patients with clear cell renal cell carcinoma that expresses PSMA
What is the current status of trial NCT02607553?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2016-06. Estimated completion is 2017-02.
What interventions are being tested in trial NCT02607553?
The interventions under investigation include: G-202 (DRUG).
Who is sponsoring clinical trial NCT02607553?
This trial is sponsored by GenSpera, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02607553's enrollment target sits among peer trials
2 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia